With $40M for Exonics, Duchenne’s Gene Therapy, CRISPR Race Heats Up – Xconomy
Xconomy |
With $40M for Exonics, Duchenne's Gene Therapy, CRISPR Race Heats Up
Xconomy The Cambridge, MA, company, seeded last year by a subsidiary of the nonprofit group CureDuchenne, will use a $40 million Series A round led by The Column Group to advance a Duchenne treatment using the gene editing technology CRISPR-Cas9. |
